

Amendments to the Claims

1. (Currently Amended) A stable composition for rapid delivery by inhalation to the lungs, and subsequently to the bloodstream, the composition comprising a therapeutically effective amount of delta-9-tetrahydrocannabinol in a pharmaceutically-acceptable semiaqueous solvent comprising an alcohol, water and a glycol, in amounts sufficient
 - (i) to aerosolize the composition to a mean mass median aerodynamic diameter in the range of from about 1 up to about 10 μ M;
 - (ii) to enhance partitioning by producing a stable clear solution near the solubility point of the delta-9-tetrahydrocannabinol;
 - (iii) wherein the concentration of glycol is about 20% to about 65% of the solvent;
 - (iv) wherein the concentration of the alcohol is about 20% to about 70% of the solvent; and
 - (v) wherein ~~composition is substantially~~ the solvent is free of a phospholipid.
2. (Previously Presented) The composition of Claim 1 wherein said delta-9-tetrahydrocannabinol comprises from about 0.1 to about 200 mg/mL.
3. (Previously Presented) The composition of Claim 2 wherein said delta-9-tetrahydrocannabinol comprises from 0.1 to 25 mg/mL.
4. (Previously Presented) The composition of Claim 2 wherein said delta-9-tetrahydrocannabinol comprises 50 mg/mL.
5. (Previously Presented) The composition of Claim 1 wherein said solvent comprises ethanol, water and propylene glycol.
6. (Currently Amended) The solvent of Claim 1 wherein the volumetric ratios of the alcohol : water: glycol are selected from those in the range of from about 20[[-]] to about 70 : about 10[[-]] to about 30 : about 20[[-]] to about 65, respectively, having a combined total of 100.
7. (Previously Presented) The solvent of Claim 5 wherein the volumetric ratios of ethanol : water : propylene glycol are selected from those in the range of from 20-70 : 10 : 20-65, respectively, having a combined total of 100.
8. (Previously Presented) The solvent of Claim 7 wherein the volumetric ratios of ethanol : water : propylene glycol are 35 : 10 : 55, respectively, having a combined total of 100.

9. (Previously Presented) The composition Claim 1 wherein the composition is in a sterile and/or preserved sealed unit-or-multi-unit dosage form comprising a container for rapid delivery by inhalation to the lungs and subsequently to the bloodstream.
10. (Previously Presented) The composition Claim 9 wherein said container comprises Type I Amber Glass with a liner.